Cardiovasculaire Geneeskunde.nl

PCSK9: From Biology to Therapy

Gilles Lambert, Jean-Claude Tardif and Nabil Seidah

10' educatie - May 23, 2015 - PACE-studio at ISA2015 - Gilles Lambert, Jean-Claude Tardif and Nabil Seidah

Video navigatie menu

  • ‘The biology of PCSK9 in humans: Just LDL-cholesterol or more?’ by Gilles Lambert 0:24
  • ‘Genetic variation at the PCSK9 locus: A contributor to CV risk?’ by Jean-Claude Tardif 2:19
  • ‘The PCSK9 protein: A key modulator of cardiovascular outcome’ by Nabil Seidah 4:22
  • Lp(a) changes upon PCSK9 inhibition 6:30
  • Theoretical safety issues with PCSK9 inhibition 7:55
  • Clinical observations on safety of PCSK9 inhibition 10:22

Tomorrow's specialists meet today's experts | Tijdens ISA2015 zijn in de PACE-studio gesprekken opgenomen, waarin Nederlandse arts-onderzoekers internationale experts interviewden over hun expertise.
ZIe ook www.pace-cme.org.

Nabil Seidah discovered the PCSK9 protein. He discusses the advances in the field since its discovery in 2002 with Gilles Lambert, who studies the biological function of PCSK9 and Jean-Claude Tardif, who presented what human genetics can tell us about the potential benefit of PCSK9-inhibiting therapy.
They share their experience with Nick van Es (AMC Amsterdam, The Netherlands) and Lotte Koopal (UMC Utrecht, The Netherlands).

Topics covered:
- The biology of PCSK9 in humans: Just LDL-cholesterol or more?
- Genetic variation at the PCSK9 locus: A contributor to CV risk?
- The PCSK9 protein: A key modulator of cardiovascular outcome

Participating Speakers:
- Gilles Lambert (University of Nantes Medical School, Nantes, France)
- Jean-Claude Tardif (Canadian Institutes of Health Research, Montréal, Canada)
- Nabil Seidah (Laboratory of Biochemical Neuroendocrinology, Montréal, Canada)

Deze inhoud is bedoeld voor medische professionals. Om dit te bekijken is registratie noodzakelijk. Registreer gratis voor onbeperkte toegang tot ons educatief materiaal.

Deel deze pagina met collega's en vrienden: